


1614



533 Rec'd PCT/PTO 1 AUG 2000

PCT  
#4 PATENT RECEIVED

SEP 11 2000

IN THE UNITED STATES PATENT  
AND TRADEMARK OFFICE

Applicants: Erik H.F. Wong *et al.*  
Serial No.: 09/599,213  
Filed: June 22, 2000  
Title: HIGHLY SELECTIVE  
NOREPINEPHRINE  
REUPTAKE INHIBITORS  
AND METHODS OF USING  
THE SAME  
Group Art Unit: To be assigned  
Examiner: To be assigned  
Attorney Docket No.: 6248.4

I hereby certify that this paper is being  
deposited with the United States Postal  
Service as first class mail, postage  
prepaid, in an envelope addressed to:  
Assistant Commissioner for Patents,  
Washington, D.C. 20231 on this date:

August 10, 2000

James J. Napoli  
Reg. No. 32,361  
Attorney for Applicants

TECH CENTER 1600/2900

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

Submitted herewith for consideration by the examiner are the documents  
identified on the accompanying Form PTO-1449 which may be considered material to  
the examination of the above-identified application.

An early and favorable action on the merits is respectfully requested.

Respectfully submitted,

MARSHALL, O'TOOLE, GERSTEIN,  
MURRAY & BORUN

August 10, 2000

By

James J. Napoli  
Reg. No. 32,361  
Attorneys for Applicants  
6300 Sears Tower  
233 South Wacker Drive  
Chicago, Illinois 60606-6402  
(312) 474-6300

## INFORMATION DISCLOSURE STATEMENT


6248.4

09/599,213

Erik H.F. Wong *et al.*

RECEIVED

June 22, 2000

AUG 14 2000  
JUL 11 2000

TECH CENTER 1600/2000

## U.S. PATENT DOCUMENTS

*Examiner Initials	Document Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
237	4,229,449	10/21/80	Melloni <i>et al.</i>	424	248.58	
↓	5,068,433	11/26/91	Melloni <i>et al.</i>	564	349	
↓	5,391,735	02/21/95	Melloni <i>et al.</i>	544	174	
↓	6,028,070	02/22/00	Heiligenstein	514	238.8	09/23/97

## FOREIGN PATENT DOCUMENTS

*Examiner Initials	Document Number	Publication Date	Country	Class	Subclass	Translation	
						Yes	No
237	2,167,407	05/11/88	Great Britain				
↓	WO99/15163	04/01/99	PCT				
↓	WO99/15176	04/01/99	PCT				
↓	WO99/15177	04/01/99	PCT				

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

237	J.J. Schildkraut, <i>The Catecholamine Hypothesis of Affective Disorders: A Review of Supporting Evidence</i> , Am. J. of Psychiatry, Vol. 122, pp. 509-22 (Nov. 1965).
↓	T.H. Svensson, <i>et al.</i> , <i>Feedback Inhibition of Brain Noradrenaline Neurons by Tricyclic Antidepressants: α-Receptor Mediation</i> , Science, Vol. 202, pp. 1089-91 (Dec. 1978).

EXAMINER


WILLIAM R. A. JARVIS  
PRIMARY EXAMINER

DATE CONSIDERED

10/5/01

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT	6248.4	09/599,213
	Erik H.F. Wong <i>et al.</i>	
	June 22, 2000	



OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)		
		E. Richelson <i>et al.</i> , <i>Blockade by Antidepressants and Related Compounds of Biogenic Amine Uptake into Rat Brain Synaptosomes: Most Antidepressants Selectively Block Norepinephrine Uptake</i> , Europ. J of Pharmacology, Vol. 104 pp. 277-86 (1984).
		C.B. Nemeroff, <i>The Neurobiology of Depression</i> , Scientific American (June 1988)(8 pages).
		M. Riva <i>et al.</i> , <i>Effect of Reboxetine, A New Antidepressant Drug, on the Central Noradrenergic System: Behavioral and Biochemical Studies</i> , J. Drug Dev., Vol. 1, no. 4, pp. 243-53 (1989).
		T. Pacholczyk <i>et al.</i> , <i>Expression Cloning of a Cocaine-and Antidepressant-Sensitive Human Noradrenaline Transporter</i> , Nature, Vol. 350, no. 28, pp. 350-56 (March 1991).
		E. Richelson, <i>Biological Basis of Depression and Therapeutic Relevance</i> , J. Clin. Psychiatry, Vol. 52, no. 6 Suppl., pp. 4-10 (June 1991).
		B. Cusack <i>et al.</i> , <i>Binding Antidepressants to Human Brain Receptors: Focus on Newer Generation Compounds</i> , Psychopharmacology, Vol. 114, pp. 559-565 (1994).
		C. Pellizzoni <i>et al.</i> , <i>Pharmacokinetics of Reboxetine in Healthy Volunteers. Single Against Repeated Oral Doses and Lack of Enzymatic Alterations</i> , Biopharm. Drug Dispos. Vol. 17. No. 7, pp. 623-33 (Oct. 1996).
		R.J. Baldessarini, <i>Depression and Mania</i> , Goodman & Gilman's The Pharmacological Basis of Therapeutics, 9 <sup>th</sup> Ed., Chapter 19, pp. 431-39, (1996)
		S.A. Montgomery, <i>Is There a Role For a Pure Noradrenergic Drug in the Treatment of Depression?</i> , Eur. Neuropsychopharmacology, Vol. 7, Suppl. 1, pp. S3-S9 (1997).
		S.A. Montgomery, <i>Reboxetine: Additional Benefits to the Depressed Patient</i> , J. Psychopharmacology (Oxf), 11:4 Abstract (1997).
		I. Hindmarch, <i>The Effects of Antidepressants on Psychomotor Function With Particular Reference to Reboxetine</i> , Eur. Neuropsychopharmacology, Vo. 7, Suppl. 1, pp. S17-S21 (1997).
		A. Frazer, <i>Pharmacology of Antidepressants</i> , J. Clinical Psychopharmacology, Vol. 17, no. 2, Suppl. 1, pp. 2S-18S (1997).

EXAMINER	WILLIAM R. A. JARVIS PRIMARY EXAMINER	DATE CONSIDERED	10/05/01
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>			

## INFORMATION DISCLOSURE STATEMENT

6248.4

09/599,213

Erik H.F. Wong *et al.*

June 22, 2000



## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

	B. E. Leonard, <i>The Role of Noradrenaline in Depression: a Review</i> , J. Psychopharmacology, Vol. II, no. 4 Suppl., pp. S39-S47 (1997).
	B. Dostert <i>et al.</i> , <i>Review of the Pharmacokinetics and Metabolism of Reboxetine, a Selective Noradrenaline Reuptake Inhibitor</i> , Eur. Neuropsychopharmacol, Vol. 7, Suppl. 1, pp. 23-35 (April 1997).
	J. Massana, <i>Reboxetine Versus Fluoxetine: An Overview of Efficacy and Tolerability</i> , J. Clin. Psychiatry, Vol. 59, Suppl 14, pp. 8-10 (1998).
	A. Harkin <i>et al.</i> , <i>Activity and Onset of Action of Reboxetine and Effect of Combination With Sertraline in an Animal Model of Depression</i> , Eur. J. of Pharmacology, pp. 1-10 (1998).
	J.C. Fleishaker <i>et al.</i> , <i>Absolute Bioavailability of Reboxetine Enantiomers and Effect of Gender on Pharmacokinetics</i> , Biopharm. Drug Dispos, Vol. 20, pp. 53-7 (1999).
	J. Massana <i>et al.</i> , <i>Reboxetine: A Double-Blind Comparison With Fluoxetine in Major Depressive Disorder</i> , Int. Clin. Psychopharmacol, Vol. 14. No. 2, pp. 73-80 (Mar. 1999).
	J.C. Fleishaker <i>et al.</i> , <i>Absolute Bioavailability of Reboxetine Enantiomers and Effect of Gender on Pharmacokinetics</i> , Biopharm. Drug Dispos. Vol. 20, no. 1, pp. 53-57 (Jan 1999).

EXAMINER

WILLIAM R. A. JARVIS  
PRIMARY EXAMINER

DATE CONSIDERED

10/05/01

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.